Gelnhausen, Germany, February 10th 2014: The organisation team of the International DDI Workshop presents the programme of the DDI 2014 - 5th International Workshop on Regulatory Requirements and Current Scientific Aspects on the Preclinical and Clin
February 10, 2014 (Newswire.com) - The overall objective of the Drug-Drug Interaction Workshop series at Marbach Castle is to improve and disseminate the scientific knowledge about drug-drug interactions (incl. food-drug and herb-drug interactions), to foster their proper preclinical and clinical investigation and communication, thereby improving the safe use of drugs in the light of ageing populations and increasing polypharmaco-therapy.
The DDI Workshop series started in May/June 2010 as an initiative of a group of international scientists and experts in the field from academia and industry. The first event was triggered by the notion that the area of drug-drug interactions is getting increasingly important and complex in view of continuously emerging new therapies, complex treatment algorithms for many widespread disease states and ageing populations in industrialized countries.
The organizers of the DDI Workshop are highly pleased to see that the DDI Workshop is now widely recognized and well established. On behalf of the organisation team Dr. Robert Hermann said: "In the 5th year the topics of the DDI Workshop are as important as 5 years ago. There is an unchanged need for scientific meetings, which offer presentation and discussion of new findings, techniques and guidelines in the area of drug-drug interactions. Attendees of former workshops appreciate the opportunity to meet with other experts once a year."
This year the 5th International Drug-Drug Interaction Workshop at Marbach Castle will take place from May 25th to 27th 2014. As in the previous years, the topics of the 5th International DDI Workshop will be covered by distinguished international scientists and experts from academia, pharmaceutical companies, contract research organizations, consultancies as well as government and regulatory agencies. The 16 speakers of this year will come from 5 different countries (Germany, Great Britain, Japan, USA and Switzerland), thereof 4 from the US. They will present scientific news, the content of Japanese PMDA- and US-FDA draft guidelines and state of the art lectures. The scientific sessions will cover regulatory aspects of drug-drug interactions (FDA draft guideline, PMDA draft guideline), herb-drug and food-drug interactions and drug-drug interactions involving drug transporters. It's the first time that herb-drug and food-drug interactions will be addressed in detail.
The organisation team decided to expand the programme and to offer also a poster session with oral presentations of selected posters. The poster session will comprise topics related to all aspect of non-clinical and clinical DDI investigations including IVIVE, modeling approaches, regulatory, pharmaco-epidemiological as well as labelling aspects of DDIs. Poster presenters need to submit an abstract (limited to 250 words) to firstname.lastname@example.org. The deadline for abstract submission is on May 3rd 2014.
The DDI Workshop offers a unique opportunity for scientific exchange and networking across company and organizational boarders, and to learn about the current state-of-the-art in the investigation of DDIs. Based on the detailed feedback received from the expert audience on additional areas of interest requiring future consideration, the structure and content of the DDI Workshop 2014 were designed. The programme of the DDI Workshop 2014 is now available on the website of cr.appliance.
More information and register: http://www.cr-appliance.com
About the DDI Workshop
The DDI Workshop is an initiative of cr.appliance in cooperation with Hartmut Derendorf, Amin Rostami-Hodjegan, and Oliver von Richter. The meeting will take place in Marbach Castle Conference Centre, located at the Lake Constance, Germany.
The organizers of the DDI Workshop are:
• Hartmut Derendorf, PhD FCP; College of Pharmacy, University of Florida, USA
• Robert Hermann, MD FCP; cr.appliance, Germany
• Amin Rostami-Hodjegan, PhD FCP; Faculty of Medical and Human Sciences, University of Manchester, UK
• Oliver von Richter, PhD FCP; Dept. Exploratory Medicine, Merck Serono, Germany